To be honest, it's not a decision that we've taken, that we would do. It's something we would need to look at carefully with respect to our aid effectiveness principles, our principles of country ownership, allowing the flexibilities of developing countries to access the medicines that are most affordable, most efficacious for them. At the same time, though, we would certainly bring their attention--and have done so on many, many occasions--to the legislation that exists in Canada. We have made them aware that those flexibilities exist in Canada, that our manufacturers do have the ability through this legislation to provide it through compulsory licensing. But it's a question of putting the decision and the country ownership within the hands of the developing country to make those decisions.
On April 16th, 2007. See this statement in context.